The purpose of this study is to compare Floseal to our standard of care (SOC) to decrease intraoperative and immediate post-operative bleeding.
A prospective randomized single-blind clinical trial will be conducted at the Hôpital du Sacré-Coeur de Montréal and Hôpital Jean-Talon. All patients admitted for total knee arthroplasty (TKA) between January 2012 and September 2013 Outcome variable: Patient receiving Floseal or SOC Variables under study: Primary end point: Need of transfusion post-op (yes/no, how many) Patient will be transfused if : Hg \< 80 g/L plus if patient is symptomatic: orthostatic hypotension, tachycardia (pulse\> 100/min, hypotension (\< 90/60), hx : CVA, CAD) Secondary end point: 1. Efficacy (during hospital stay) * Pre-op and post-op Hg (\> 100; 80-100; \<80) * Hemovac blood drainage (ml) * Per operative bleeding (ml) 2. Safety (Follow up: 6wks, 6 ms, 12 ms, 24 ms) * Post-op complications: infection, pain, oedema, allergic reaction. * Functional outcomes: Knee Society Score (KSS), Western Ontario and McMaster Universities questionnaire (WOMAC), International knee documentation committee form (IKDC)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
132
Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
Hopital du sacre coeur de montreal
Montreal, Quebec, Canada
Need of transfusion post-op (yes/no, how many)
Time frame: post op day 1 to 7
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.